Supplementary Figure 7: Tumour growth curves in mice and cell sensitivities of SHLD mutant cells to DNA damaging agents.
From: Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
a, Tumour growth curves of PDX mice cohorts treated with vehicle or olaparib in Fig 7a; points are means, with lines representing s.d. for each of cohorts 1-4. b, AUC for clonogenic survival assay presented in Fig 7c. N=3 independent experiments except BRCA1ko and C20orf196ko where n=4, and BRCA1ko/FAM35Ako where n=2. c, AUC for clonogenic survival assay presented in Fig 7d. N=3 independent experiments except WT where n=6 and BRCA1ko/FAM35Ako where n=2. b-c Bars represent mean ± SEM, one-way Anova; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns=not significant (p≥0.05). Individual data points plotted over bars; statistical source data including the precise p values can be found in Supplementary Table 5. d, GFP-FAM35A foci are not affected by depletion of FANCD2; representative images (left panel) and quantification (right panel). Bars represent means from 2 independent experiments, with individual data points plotted over bars. Scale bar 10µm. e, Graphical summary of SHLD2FAM35A domains and their function.
